# Recovery Peptide FAQ — GHK-Cu, TB-500, BPC-157 — Prime Peptide Labs

> Frequently asked questions about three Recovery & Tissue Repair research peptides — GHK-Cu, TB-500, and BPC-157 — answered from the peer-reviewed literature, with citations.

Direct, citation-anchored answers to the questions readers bring most often to these three recovery peptides.

## What does a GHK-Cu peptide do?

GHK-Cu is a copper-carrying tripeptide that signals skin and connective-tissue cells to rebuild their matrix. At very low (picomolar to nanomolar) concentrations it tells dermal fibroblasts — the cells that make the skin's structural fabric — to produce more collagen, elastin, glycosaminoglycans, and the proteoglycan decorin, while rebalancing the enzymes that break matrix down against their inhibitors [6]. The copper ion itself enables collagen and elastin cross-linking and acts as an antioxidant. At the gene level, it has been shown to shift expression of roughly 31.2% of human genes at a 50%-or-greater threshold toward repair and antioxidant programs [2]. Most documented human benefit is in topical skin applications [1].

## What is GHK-Cu and how does it work?

GHK-Cu is the linear tripeptide glycyl-L-histidyl-L-lysine chelated 1:1 to a copper(II) ion. The same GHK sequence appears naturally inside type I collagen and in SPARC/osteonectin, so the body already uses this motif — copper coordination is what activates most of its reported functions [4]. It works by acting as both a copper chaperone (delivering copper to sites where it is needed for enzyme activity) and a direct signaling molecule that tells fibroblasts to produce collagen and elastin and tells the immune response to tone down inflammatory mediators [6]. Its effects on gene expression — stimulating ubiquitin-proteasome, DNA-repair, and antioxidant pathways — were mapped by Connectivity Map analysis [2].

## Is GHK-Cu peptide really anti-aging?

There is real, if modest and mostly topical, human evidence for skin benefits. Topical GHK-Cu increased collagen production in about 70% of treated women, outperforming vitamin C (50%) and retinoic acid (40%) in the same comparison, and reviews document placebo-controlled improvements in skin laxity, fine lines, and wrinkle depth [4]. Two honest caveats apply: the widely quoted "~4,000 genes" figure is an extrapolation from a verified 31.2%-at-50%-threshold statistic (roughly 2,100 genes at that bar) [2], and GHK penetrates intact skin poorly, limiting how much reaches the dermis without delivery aids like microneedles or palmitoylation [1]. Systemic or injectable anti-aging use is unproven.

## What is the difference between GHK and GHK-Cu?

GHK is the bare tripeptide glycyl-histidyl-lysine. GHK-Cu is that same tripeptide *chelated* to a copper(II) ion. Copper coordination is required for most of GHK's reported bioactivities — including collagen stimulation, lysyl-oxidase cross-linking, and the superoxide-dismutase-like antioxidant action — so the two forms should not be treated as equivalent [4]. The distinction matters when reading studies: if a paper used the free tripeptide, its findings may not apply to the copper complex, and vice versa. Most of the collagen and anti-aging literature uses GHK-Cu.

## What is TB-500?

TB-500 is a synthetic, N-terminally acetylated heptapeptide with the sequence Ac-LKKTETQ. This seven-amino-acid stretch corresponds to residues 17-23 of thymosin beta-4, a 43-amino-acid endogenous protein, and it is the conserved actin-binding region of the beta-thymosin family [12]. The name can mislead: in commerce and anti-doping science, "TB-500" denotes the short fragment, but the vast majority of published efficacy research uses the full-length parent protein, which is roughly five times larger [8]. Whether the fragment reproduces the parent protein's effects is not established in controlled human trials.

## What does TB-500 stand for and what does TB stand for in TB-500?

"TB" refers to *thymosin beta* — specifically thymosin beta-4, the natural protein from which TB-500 is derived. The fragment designation comes from the fragment's role as the actin-binding 17-23 segment of that protein [12]. The "500" has no fixed biological meaning; it is a research-community designation for this particular synthetic fragment. The important nuance is that in practice, "TB-500" in commerce and anti-doping means the short heptapeptide, while most published healing studies used the full-length Tβ4 protein [8].

## What is TB-500 used for in research?

In research, TB-500 and — more often — full-length thymosin beta-4 are studied for tissue repair driven by actin regulation: cell migration into wounds, new blood-vessel growth, reduced scar formation, and anti-inflammatory signaling, with models in dermal wounds, cornea, heart, and CNS [10]. A human Phase 1 study of full-length Tβ4 in 40 volunteers focused on safety and pharmacokinetics rather than a specific indication [11], and a rat study examined dose-dependent neurological recovery after embolic stroke [9]. No completed controlled clinical trials of the TB-500 fragment itself exist for any indication [8].

## Does TB-500 work for muscle tears and recovery from exercise?

There is no controlled human evidence that the TB-500 fragment helps muscle tears or exercise recovery. The mechanistic rationale comes from thymosin beta-4's role in cell migration and repair signaling [10], but a 2026 Sports Medicine review of unapproved peptides for musculoskeletal injuries and athletic performance concluded that favorable animal results have not been matched by rigorous human safety or efficacy data, and that these compounds operate largely outside regulatory oversight [8]. Notably, in a muscular-dystrophy mouse model, chronic Tβ4 increased regenerating fibers but did *not* improve muscle strength [10]. TB-500 is also prohibited in sport by WADA [8].

## What does BPC-157 do in the body?

In animal models, BPC-157 is described as a cytoprotective and regenerative peptide whose healing effects are tied most consistently to *angiogenesis* — encouraging the growth of new blood vessels into injured tissue by making blood-vessel cells more responsive to the VEGFR2 growth signal [16]. In rat models it has accelerated healing of gastric ulcers [17] and reduced healing time for gut and tendon injuries. Additional reported pathways include modulation of nitric oxide, growth-hormone-receptor sensitization in tendon cells, and brain-gut axis signaling. Human evidence is limited to three small pilot studies, so the full picture in people remains unclear [14].

## Is BPC-157 a growth hormone?

No. BPC-157 is not a growth hormone and is not growth hormone in any form. It is a synthetic fifteen-amino-acid peptide derived from a protein in gastric juice. The connection that sometimes causes confusion: in tendon cells, BPC-157 has been reported to sensitize the *growth-hormone receptor*, potentially amplifying the effect of the body's own growth hormone [16]. Making a receptor more sensitive is not the same as being a growth hormone — BPC-157 does not replace or mimic growth hormone itself, and growth hormone and BPC-157 are entirely different molecules.

## Does BPC-157 work immediately?

The peptide clears from the bloodstream quickly. The first formal pharmacokinetic work in rats and beagle dogs found a very short elimination half-life — under 30 minutes — with rapid breakdown into small fragments that re-enter normal amino-acid metabolism [15]. A short half-life means the intact peptide does not linger after dosing. Whether any healing *effect* appears quickly is a separate question: animal healing outcomes in published studies are measured over days to weeks, not as immediate events [17]. This desk does not advise on use or timing.

## Does BPC-157 damage the liver?

The available data do not show liver harm, but the dataset is very thin. In the 2025 first-in-human intravenous safety pilot, BPC-157 up to 20 mg in two healthy adults produced no measurable changes in hepatic, cardiac, renal, thyroid, or glucose biomarkers, and no adverse events were observed [13]. That is reassuring, but it is two people in a safety pilot, not a liver-safety study. The broader literature is clear that without long-term, large-sample human data, the overall safety profile remains genuinely unknown [14]. Nothing here is medical advice.

---

A plain-language reading desk for recovery-peptide research — citations on every claim, no products, no prescriptions.